#ventricular-tachycardia #arrhythmia-management #catheter-ablation #antiarrhythmic-drugs #implantable-cardioverter-defibrillator

VT Management

Definition

Ventricular tachycardia (VT) management is the set of acute and chronic strategies that terminate sustained VT, prevent recurrence and reduce sudden cardiac death. It spans acute pharmacologic and electrical termination, chronic antiarrhythmic therapy, device therapy (ICD and its programming), catheter ablation of the arrhythmogenic substrate, and syndrome-specific treatment in inherited arrhythmias. The choice depends on haemodynamic stability, the underlying substrate (ischaemic, non-ischaemic, inherited), ventricular function, and whether the goal is acute termination, symptom control, shock reduction or mortality reduction.

Key Concepts

Initial assessment

Treat wide-complex tachycardia as VT by default until proven otherwise; the first branch point is haemodynamic stability, not the rhythm diagnosis. See concepts/Wide-Complex-Tachycardia.
Obtain a 12-lead ECG when possible, assess for structural disease and LV function, and correct reversible triggers: ischaemia, hypo-kalaemia/hypomagnesaemia, QT-prolonging drugs, fever in Brugada syndrome and decompensated heart failure. (sources/VA-SCD-ESC-2022, rating: very high)
Two questions run in parallel: acute termination and chronic prevention of recurrence and SCD.

Acute termination

Scenario	First-line approach	Key detail
Unstable or pulseless VT	Synchronised cardioversion; unsynchronised defibrillation if pulseless	Do not delay for drug therapy
Stable monomorphic VT in structural heart disease	IV amiodarone	IV procainamide is Class IIa where haemodynamically tolerated; avoid verapamil/diltiazem
Electrical storm in structural heart disease	Triggers + deep sedation + IV amiodarone + IV beta-blocker	Procainamide IIa; emergency ablation Class I for refractory SMVT; mechanical support if unstable
Torsades de pointes / acquired LQTS	IV magnesium + potassium correction	Stop QT-prolonging drugs; isoproterenol or pacing for bradycardia-dependent episodes
CPVT storm	IV beta-blocker	Isoproterenol is contraindicated
Brugada or idiopathic VF storm	IV isoproterenol	Quinidine for chronic suppression
Fascicular VT	Verapamil	Verapamil-sensitive Purkinje re-entry; ablation is definitive

Sources for the acute algorithm: (sources/VA-SCD-ESC-2022, rating: very high). Fascicular VT: (sources/lpfvt-svt-circep-2017, rating: high).

Electrical storm

Definitions and prognosis

Defined as ≥3 episodes of sustained VT, VF or appropriate ICD shocks within 24 hours; the ESC definition adds a ≥5-minute separation between episodes, and distinguishes incessant VT — continuous sustained VT that recurs promptly despite repeated intervention over hours. (sources/va-scd-aha-2017, rating: very high)
Storm is most common in ICD recipients with structural heart disease, driven by an unstable re-entrant substrate, sympathetic activation, electrolyte disturbance or ischaemia; in inherited syndromes it is driven by triggered activity (catecholamine-mediated DADs in CPVT, short-coupled PVCs in IVF, adrenergic facilitation in Brugada). It is associated with increased long-term mortality independent of the underlying disease and the number of shocks. (sources/VA-SCD-ESC-2022, rating: very high)

Stepwise management (ESC 2022)

Correct reversible triggers (Class I): potassium and magnesium, ischaemia, QT-prolonging drugs, fever in Brugada syndrome, decompensated heart failure. (sources/VA-SCD-ESC-2022, rating: very high)
Deep sedation and analgesia (Class I): reduces sympathetic tone; intubation and ventilation for refractory cases.
Aetiology-directed antiarrhythmic therapy: in structural heart disease, IV amiodarone plus IV beta-blocker (Class I; avoid beta-blockers in haemodynamic compromise), with IV procainamide Class IIa if monomorphic VT is haemodynamically tolerated. In CPVT, IV beta-blockers (Class I) and no isoproterenol; in Brugada or IVF, IV isoproterenol Class IIa; in acquired LQTS with torsades, IV magnesium and potassium (Class I), then isoproterenol or pacing. (sources/VA-SCD-ESC-2022, rating: very high)
Emergency catheter ablation (Class I for SMVT): for incessant VT or storm refractory to antiarrhythmic drugs; epicardial access may be needed in non-ischaemic disease. Ablation targets re-entrant substrate and is not effective against triggered activity. VANISH2 did not significantly reduce storm events with first-line ablation (HR 0.95), so its benefit is mainly chronic suppression rather than acute storm prevention. (sources/VA-SCD-ESC-2022, rating: very high) (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
Mechanical circulatory support: intra-aortic balloon pump, percutaneous LVAD or ECMO to maintain haemodynamics during ablation or as a bridge in refractory storm. (sources/VA-SCD-ESC-2022, rating: very high)
Autonomic modulation: left cardiac sympathetic denervation is Class IIa when drugs fail, particularly in CPVT or refractory structural storm; thoracic epidural anaesthesia (Class IIb) and emergency stellate ganglion blockade are alternatives. (sources/VA-SCD-ESC-2022, rating: very high)

ICD shocks terminate episodes but do not prevent them, and repeated shocks are themselves associated with worse outcomes; storm management therefore combines trigger correction, reprogramming (ATP first, longer detection) and substrate therapy rather than relying on shocks. (sources/icd-programming-hrs-2019, rating: high)
LCSD in storm: in LQTS patients with electrical storm, LCSD reduced the annual incidence of ICD shocks by 90%, and in CPVT it reduced major cardiac events from 86% to 21% over a median 37 months. (sources/lqts-nejm-2025, rating: very high) (sources/cpvt-jcm-2024, rating: medium)

Chronic drug therapy

Beta-blockers are foundational antiadrenergic therapy — Class I in CPVT and LQTS, and an adjunct in structural-heart-disease VT. (sources/VA-SCD-ESC-2022, rating: very high)
Amiodarone is first-line for recurrent ICD shocks despite optimal programming; OPTIC showed the lowest shock rate with amiodarone plus a beta-blocker. It reduces shocks but has no mortality benefit in HFrEF, and SCD-HeFT suggested harm in NYHA III (HR 1.44). (sources/amiodarone-cvdrug-2020, rating: high) (sources/icd-hfref-scdheft-nejm-2005, rating: very high)
Sotalol is an alternative when LVEF is preserved and renal function permits; Class IC agents (flecainide, propafenone) are contraindicated in structural heart disease because of CAST-era proarrhythmia. (sources/flecainide-af-europace-2011, rating: medium)
Potassium optimisation: targeting high-normal potassium (4.5–5.0 mmol/L) reduced the composite of VT, ICD therapy, arrhythmia hospitalisation or death (HR 0.76; NNT 12.3) in ICD patients. (sources/potcast-nejm-2025, rating: very high)

Device therapy

Secondary prevention: ICD is Class I after survived cardiac arrest or haemodynamically compromising sustained VT. (sources/VA-SCD-ESC-2022, rating: very high)
Primary prevention: LVEF ≤35% remains the main criterion, derived from SCD-HeFT (ICD HR 0.77). In non-ischaemic DCM, DANISH showed no all-cause mortality benefit (HR 0.87) but halved SCD (HR 0.50), with benefit concentrated in patients younger than 70. (sources/icd-hfref-scdheft-nejm-2005, rating: very high) (sources/icd-nicm-danish-nejm-2016, rating: high)
Programming: ATP first (8 pulses at ~88% of VT cycle length), with high-rate detection and long detection windows, reduces shocks. (sources/icd-programming-hrs-2019, rating: high) A therapy-reduction bundle also lowered mortality by 30% versus conventional programming in a meta-analysis. (sources/vt-dcm-hrs-2018, rating: high)
S-ICD cannot deliver ATP, so it is a poorer choice when painless termination of monomorphic VT is a priority. See entities/S-ICD.

Antitachycardia pacing (ATP)

ATP delivers a burst of paced beats faster than the VT cycle length through the ICD lead, aiming to penetrate the excitable gap and terminate a re-entrant VT without a shock. It is painless, immediate and the default first therapy in the VT zone.

Parameter	Typical prescription	Evidence / note
Burst length	8 pulses	8-pulse burst as effective as 15-pulse (ADVANCE-D)
Pacing cycle length	~88% of VT cycle length	With a 10 ms scan decrement between bursts
Bursts before shock	Up to 2	A second burst raises first-burst efficacy from 64% to 83%
Fast VT	188–250 bpm (CL 240–320 ms)	Burst is superior to ramp for fast VT (PITAGORA ICD)
During capacitor charging	ON where available	Safe and effective

Shock reduction: ATP first-line reduced shocks by 71% relative versus shock-first programming in PainFREE Rx II; because appropriate shocks were associated with a five-fold mortality increase in SCD-HeFT, ATP is the main programmable lever for reducing shock burden. (sources/icd-programming-hrs-2019, rating: high)
Failure and harm: ATP can accelerate VT or degenerate it into VF, particularly with fast or poorly organised VT. In a canine ischaemia-reperfusion model, RV apical ATP accelerated VT in ~9% and caused VF in ~5% of trains; the corresponding rates for His-bundle ATP were lower, but that site remains preclinical. (sources/his-atp-vt-jce-2023, rating: medium)
ATP is ineffective against VF, although ATP during charging in the VF zone is used to try to terminate VT before the shock. The S-ICD has no pacing capability at all. (See entities/S-ICD.)
Alternative delivery sites: LBBA ATP terminated 70.2% of VT episodes versus 47.3% with RV ATP in the same canine model, whereas His ATP was safer but not more effective; neither is a programmable option in current ICDs. (sources/lbbap-atp-jaccep-2026, rating: medium) (sources/his-atp-vt-jce-2023, rating: medium)

Catheter ablation

General principle: activation, entrainment, pace and substrate mapping identify the re-entrant circuit or focal origin; ablation targets the critical isthmus, late potentials/LAVA, scar channels or the entire scar. Non-inducibility is the traditional endpoint but is imperfect, and the consistent randomised benefit is fewer ICD therapies rather than lower mortality. (sources/vt-ablation-jaccep-2019, rating: high)
Ischaemic cardiomyopathy: VANISH2 supports first-line ablation over antiarrhythmic drugs (primary composite 50.7% vs 60.6%; HR 0.75, P=0.03), driven mainly by fewer treated VT episodes below the ICD detection limit (HR 0.26). Mortality (HR 0.84) and VT storm (HR 0.95) were not significantly reduced; drug adverse events led to discontinuation in 21.6%. (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
Non-ischaemic DCM: substrate is patchy midwall/epicardial fibrosis with anteroseptal and inferolateral patterns. Acute success is 38–73%, recurrence 46–60% at 1 year, and complications up to 9%. Endo-epicardial scar homogenisation improved VA-free survival versus limited-substrate ablation (64% vs 39% at 14 months; HR 0.48), but septal and midmyocardial scar often remains inaccessible. (sources/vt-dcm-hrs-2018, rating: high) (sources/vt-ablation-nicm-jacc-2016, rating: medium)
Epicardial ablation: required in 32–63% of non-ischaemic patients and in ARVC, Chagas disease, Brugada syndrome and cardiac sarcoidosis; it carries access-specific risks including haemopericardium (5–14%), phrenic nerve injury and pericarditis. See concepts/Epicardial-VT-Ablation. (sources/epicardial-vt-ablation-jaccep-2024, rating: high)
Pulsed field ablation: high-voltage focal PFA achieved 92% acute success, 81.8% 180-day freedom from VT/VF or ICD shock and a 98% reduction in VT/VF burden in the first-in-human VCAS trial, with transmural lesions demonstrated by paired epicardial mapping; it remains investigational. (sources/pfa-vt-circ-2025, rating: high)
Indications: recurrent monomorphic VT despite AADs, AAD intolerance, incessant VT or storm, and bundle-branch re-entrant or fascicular VT. Emergency ablation is Class I for SMVT-related storm refractory to drugs. (sources/VA-SCD-ESC-2022, rating: very high)
Referral timing: patients are often referred late; in one tertiary cohort 63% had ≥2 prior VT episodes, and early referral was associated with lower recurrence (HR 0.37). This is observational, not randomised. (sources/vt-ablation-jaccep-2019, rating: high)

Syndrome-specific management

Syndrome	Key points
CPVT	Non-selective beta-blocker (nadolol/propranolol) Class I; add flecainide; LCSD for refractory disease; ICD plus beta-blocker plus flecainide after aborted cardiac arrest. See entities/CPVT. (sources/VA-SCD-ESC-2022, rating: very high) (sources/cpvt-jcm-2024, rating: medium)
LQTS / torsades de pointes	Beta-blockers, avoid QT-prolonging drugs, correct K/Mg, pacing or isoproterenol for bradycardia-dependent TdP; mexiletine for LQT3. See entities/Long-QT-Syndrome and concepts/Torsades-de-Pointes. (sources/VA-SCD-ESC-2022, rating: very high)
Brugada syndrome	Isoproterenol for electrical storm; quinidine for suppression; ICD for survivors of cardiac arrest. See entities/Brugada-Syndrome. (sources/VA-SCD-ESC-2022, rating: very high)
Idiopathic VF	ICD Class I; isoproterenol and quinidine for recurrent short-coupled PVC-triggered VF. See entities/Idiopathic-Ventricular-Fibrillation. (sources/VA-SCD-ESC-2022, rating: very high)
Short QT syndrome	Quinidine first-line; amiodarone and sotalol are ineffective in SQTS1. See entities/Short-QT-Syndrome. (sources/VA-SCD-ESC-2022, rating: very high)
ARVC	Beta-blockers for VA reduction, flecainide as add-on; ICD for arrhythmic syncope or high-risk phenotype, with ATP-capable programming. See entities/ARVC. (sources/VA-SCD-ESC-2022, rating: very high)
HCM	ICD guided by the HCM risk calculator; beta-blockers or verapamil for symptoms; rhythm control for AF uses sotalol, dofetilide or amiodarone. See concepts/HCM-Risk-SCD. (sources/esc-cmp-2023, rating: very high) (sources/HCM-NEJM-2025, rating: very high)

Special populations

Pregnancy: electrical cardioversion is safe and uses the same energy as in non-pregnant patients; antiarrhythmic choice is constrained by fetal safety. See concepts/Arrhythmia-in-Pregnancy. (sources/arrhythmia-pregnancy-hrs-2023, rating: very high)
Periprocedural device care: EMI, magnet responses and temporary inhibition differ by device type. See concepts/Periprocedural-CIED-Management.

Contradictions / Open Questions

First-line ablation versus drugs is not settled across substrates. VANISH2 was positive for its composite endpoint in ischaemic cardiomyopathy, but mortality and VT storm were not significantly reduced and the trial excluded non-ischaemic disease; guidelines still recommend drugs first, with ablation for refractory VT. The benefit is therefore chronic suppression, not proven mortality reduction. (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
Primary-prevention ICDs in non-ischaemic DCM remain contested. SCD-HeFT and DANISH disagree on all-cause mortality, and DANISH's benefit was age-dependent and potentially diluted by 58% CRT use; which DCM patients still benefit is unresolved. (sources/icd-hfref-scdheft-nejm-2005, rating: very high) (sources/icd-nicm-danish-nejm-2016, rating: high)
DCM ablation evidence is weaker than ischaemic evidence. Outcomes come from heterogeneous single-centre registries, with no RCT comparable to VANISH2; a negative LGE scan does not exclude diffuse midwall substrate. (sources/vt-dcm-hrs-2018, rating: high)
Amiodarone trades efficacy for toxicity. It reduces ICD shocks but does not improve survival in HFrEF and may harm NYHA III patients; the optimal duration and the role of early ablation instead are unresolved. (sources/amiodarone-cvdrug-2020, rating: high) (sources/icd-hfref-scdheft-nejm-2005, rating: very high)
Device choice involves a therapeutic trade-off. The S-ICD avoids intracardiac leads but cannot deliver ATP; the advantage depends on the probability that painless VT termination will be needed. See entities/S-ICD.
The potassium target is not yet standard care. POTCAST was open-label and used a composite endpoint; whether 4.5–5.0 mmol/L should be routinely targeted, and in whom, is unproven. (sources/potcast-nejm-2025, rating: very high)
Conduction-system ATP is preclinical only. His-bundle and LBBA ATP have been tested in a canine ischaemia-reperfusion model, with different efficacy results by site; no human outcome data exist. See concepts/ICD-Programming. (sources/his-atp-vt-jce-2023, rating: medium) (sources/lbbap-atp-jaccep-2026, rating: medium)
ATP is not risk-free. The same burst that terminates VT can accelerate it or degenerate it into VF, and the predictors of ATP-induced acceleration in humans are poorly defined; the ~9% acceleration and ~5% VF rates come from a canine model and may not translate. The trade-off between more aggressive ATP (fewer shocks) and safer ATP (fewer accelerations) has no randomised answer. (sources/his-atp-vt-jce-2023, rating: medium) (sources/icd-programming-hrs-2019, rating: high)
The electrical-storm sequence is expert-opinion based. No RCT establishes the optimal order of trigger correction, sedation, antiarrhythmic drugs, ablation and mechanical support, and the timing of emergency ablation in haemodynamically unstable patients is Level C evidence. VANISH2 further shows that first-line ablation does not significantly reduce storm events. (sources/VA-SCD-ESC-2022, rating: very high) (sources/vt-ablation-vanish2-nejm-2025, rating: very high)
Non-ischaemic ablation lacks randomised evidence. The endo-epicardial homogenisation benefit comes from a non-randomised, operator-selected cohort with 14-month follow-up; there is no VANISH2 equivalent in non-ischaemic cardiomyopathy. (sources/vt-ablation-nicm-jacc-2016, rating: medium) (sources/vt-dcm-hrs-2018, rating: high)
Transmurality is a trade-off, not a pure benefit. Deeper lesions may eliminate intramural circuits but can ablate viable myocardium and impair contractility; the optimal lesion depth and the patients who benefit from transmural homogenisation are undefined. (sources/pfa-vt-circ-2025, rating: high)
Ventricular PFA is unconfirmed. VCAS was a single-arm first-in-human study of 26 patients with 6-month follow-up and a confidence interval overlapping conventional outcomes; randomised comparison is required before it can displace RF. (sources/pfa-vt-circ-2025, rating: high)

Connections

Related to concepts/Wide-Complex-Tachycardia — rhythm diagnosis before treatment
Related to concepts/Electrical-Storm — the acute crisis form
Related to concepts/Antiarrhythmic-Drugs and entities/Amiodarone — pharmacologic therapy
Related to concepts/Beta-Blockers — antiadrenergic therapy
Related to concepts/Potassium-and-Ventricular-Arrhythmias — electrolyte optimisation
Related to entities/ICD, concepts/ICD-Programming and entities/S-ICD — device therapy
Related to concepts/VT-Ablation — general ablation principles, mapping and technology
Related to concepts/VT-Ablation-Ischemic-Cardiomyopathy — ischaemic substrate ablation
Related to concepts/VT-Ablation-Nonischemic-Cardiomyopathy — intramural and epicardial substrate
Related to concepts/Epicardial-VT-Ablation — pericardial access and epicardial mapping
Related to concepts/Ventricular-PFA — emerging ventricular energy source
Related to concepts/PVC-Mapping-Ablation — mapping and ablation technique
Related to concepts/Left-Cardiac-Sympathetic-Denervation — refractory VT and CPVT
Related to concepts/VA-Risk-Stratification-DCM and entities/DCM — non-ischaemic substrate
Related to entities/ARVC, entities/HCM and concepts/HCM-Risk-SCD — cardiomyopathy-specific risk
Related to entities/CPVT, entities/Long-QT-Syndrome, concepts/Torsades-de-Pointes, entities/Brugada-Syndrome, entities/Idiopathic-Ventricular-Fibrillation and entities/Short-QT-Syndrome — inherited arrhythmia syndromes
Related to concepts/Fascicular-Ventricular-Tachycardia — verapamil-sensitive VT
Related to concepts/Arrhythmia-in-Pregnancy and concepts/Periprocedural-CIED-Management — special situations
Related to concepts/Sudden-Cardiac-Death — the outcome being prevented